FLGT

Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing services for physicians, clinicians, and patients to diagnose rare genetic disorders and enable precision medicine. The company offers a broad menu of genetic tests including single-gene testing, multi-gene panels, exome sequencing, and genome sequencing across therapeutic areas such as oncology, reproductive health, cardiology, and neurology. Fulgent significantly expanded its operations during the COVID-19 pandemic by developing and deploying widespread diagnostic testing capabilities, though the company continues to focus on its core genetic testing business. The company operates CLIA-certified and CAP-accredited laboratories utilizing advanced sequencing technologies and bioinformatics platforms.